Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
about
Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.Efavirenz in the therapy of HIV infection.Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?AtriplaR/anti-TB combination in TB/HIV patients. Drug in focusEffectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings.Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial.The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, UgandaAntiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.Absence seizures associated with efavirenz initiationEfavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical TrialThe impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167.Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.Antiretroviral therapy for children in resource-limited settings: current regimens and the role of newer agents.Pharmacokinetics of Efavirenz at a High Dose of 25 Milligrams per Kilogram per Day in Children 2 to 3 Years Old.Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients.Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.A 33-year-old patient with human immunodeficiency virus on antiretroviral therapy with efavirenz-induced complex partial seizures: a case report.Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO.Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.
P2860
Q33593775-8662F1ED-E3C7-42BA-A639-DF4D42439ECAQ33607011-2D1EF178-A6D9-4C7C-AFE9-8D2B73982125Q33914723-A2558B20-307D-4078-A991-7309BCA28A80Q34083071-45240BC6-82B7-4F41-86DA-0218CA5E0FFAQ34571594-04DF7DCF-FE30-41BB-98AD-B82231882397Q34997616-D9B24975-5748-465E-8176-8F1C088C7E80Q35154032-AE943BCC-60F7-4595-B9D7-6F61176682AEQ35547048-5164BBDE-B0A7-4556-ACD5-017D3FE08CB1Q35752638-6B966656-C518-46F5-9CE6-080A44DD20D5Q36306986-B683F564-68A1-47BB-ADB5-400F56BDE4EAQ37030715-7693CD04-080D-4405-A539-8DE78CDBBE66Q37299209-39669632-DB72-4A58-B0CE-705B4E17123DQ37429325-75B99850-4A69-41B6-81A4-5480F200734AQ37519804-DA125899-BB77-4232-B494-5AA554205D68Q37544540-A7AD4199-E470-4D99-B135-0431637F7555Q37835819-93BFDBD5-001E-4FC9-95BB-F06038293C1DQ37866289-C3015BE2-008C-4D8C-B0CD-114B835EA3F2Q37925813-D23A4C96-E118-432A-AEFC-667EBE7C7E7AQ38377051-7A8B28F7-BCDC-4747-958F-3E78B363CD4AQ39231462-599A173A-D5E2-40F0-8A73-11AE34FF8982Q40050910-12010D50-4C05-412E-87E6-BC902432FAC4Q40117598-AD97A7B9-9FD1-40EE-A40E-B63290C096ECQ40722214-762F5684-8E62-4F98-9379-30F4D3F2216FQ45256524-506A6390-2C77-46CF-8249-3F08B54B238C
P2860
Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Is the recommended dose of efa ...... iency virus-infected children?
@en
Is the recommended dose of efa ...... iency virus-infected children?
@nl
type
label
Is the recommended dose of efa ...... iency virus-infected children?
@en
Is the recommended dose of efa ...... iency virus-infected children?
@nl
prefLabel
Is the recommended dose of efa ...... iency virus-infected children?
@en
Is the recommended dose of efa ...... iency virus-infected children?
@nl
P2093
P2860
P50
P356
P1476
Is the recommended dose of efa ...... iency virus-infected children?
@en
P2093
Boubacar Nacro
Déborah Hirt
Emmanuelle Zoure
François Rouet
Hervé Hien
Hélène Peyrière
Jean-Marc Tréluyer
Mathieu Olivier
Philippe Msellati
Saik Urien
P2860
P304
P356
10.1128/AAC.01594-08
P407
P577
2009-07-27T00:00:00Z